



WORLD
CONGRESS

FORMERLY KNOWN AS



5-6 FEBRUARY, 2019 | 200 ALDERSGATE | LONDON | UK

ALLEN & OVERY

Bird & Bird

C/M/S/
Law. Tax

choose:
newjersey



COVINGTON



Goldman
Sachs



illumina®

SVBLEERINK[®]

Lilly

Medtronic



WHITE & CASE



Confirmed speakers include

Graziano Seghezzi, Managing Partner, Sofinnova Partners
Nigel Sheail, Head of BD&L, Novartis
Sander Slootweg, Managing Partner, Forbion
Francesco De Rubertis, Co-Founder and Partner, Medixi
David Pinniger, Fund Manager - Biotechnology, Polar Capital
Alex Pasteur, Partner, F-Prime Capital Partners
Tim Haines, Managing Partner, Abingworth
Jochen Gann, Head of Corporate Finance and M&A, Boehringer Ingelheim
Miriam Frieden, VP of Search & Evaluation, Novo Nordisk
Tom Burt, Partner, Crossover Fund, Sofinnova
Deborah Harland, Partner, SR One
Johnston Erwin, VP Corporate Bus. Dev., Eli Lilly
Geraldine O'Keeffe, Partner Public Equities, LSP
Ivo Staijen, Portfolio Manager, HBM Partners
Sarah Cole, Partner, Takeda Ventures
Jasper Bos, SVP and Managing Director, M Ventures
Patrik Sobocki, Investment Manager, Industrifonden
Yochi Slonim, CEO, Anima Biotech
Juan Garcia, Managing Partner, Bioseed Capital
Søren Møller, Managing Partner, Novo Seeds
Andrew Hotchkiss, CEO, Immunocore
Nerida Scott, VP, New Ventures & Transactions, Johnson & Johnson
Bart Van Hooland, Founding Partner, DROIA
Dmitry Kuzmin, Managing Partner, 4BIO Capital Partners
Alexis Normand, Head of Embleema Blockchain Consortium, Embleema
Clive Cookson, Science Editor, Financial Times
Fiona de Hemptinne, Partner, UCB Ventures
Stephan Lensky, CBO, EpimAb
Mark Hahnel, Associate Founder, Genomes.io
Gary Waanders, Managing Director Healthcare Research, Bryan, Garnier & Co.
Adrian Dawkes, Managing Director, PharmaVentures
Natalie Pankova, COO, Project Shivom
Josh Richardson, Managing Director, Longitude Capital
Anton Ussi, Operations & Finance Director, EATRIS
Adam Kostyal, Senior Vice President, Nasdaq
Mattias Häggblom, Portfolio Manager - Global

Healthcare, Swedbank Robur
Jørgen Drejer, CEO, Saniona
Patrick Van Beneden, Partner, Gimv
Chandra P. Leo, Partner, HBM Partners
Mick Cooper, Healthcare & Life Sciences Analyst, Trinity Delta
Anthony Joseph, CTO, Unite Genomics
John Power, CEO & Managing Director, Aerogen
Trevor Leighton, VP Market Access, Argenx
Andy Smith, Director-Analyst, Healthcare, Edison
Jason Foster, Managing Partner, Health Equity Consulting
Shaun Grady, VP Global Business Development, AstraZeneca
Andrew Levin, Managing Director, RA Capital
Hubert Birner, Managing Partner, TVM Capital
Jackie Hunter, Chief Executive, BenevolentBio
Sean Marett, CBO & CCO, BioNTech
Piers Morgan, CFO, Verona Pharma
Harpreet Singh, CEO, Immatics
Boris Zaitra, Head of Group M&A, Roche
Franz-Warner Haas, COO, CureVac
Dominic Schmidt, Partner, Syncona
Lord Drayson, CEO, Sensyne Health
Katherine Cohen, Venture Partner, Panacea Venture
Dimitri Dimitriou, CEO, ImmuPharma
Nikolaj Sorensen, CEO, Orexo
Thomas Holm Pedersen, CEO, NMD Pharma
Carole Longson, former Director of NICE and CSO, ABPI
John Dawson, CEO, Oxford BioMedica
Laia Crespo, Head of Europe, Sanofi Ventures
Aditya Puri, Partner – Investments, Xeraya Capital
Tim Luker, Sr. Director, Emerging Technology & Innovation, BD, Eli Lilly
John Bowis, International Health Policy Advisor
Carina Namih, Partner, Episode 1
John Hodgson, Independent Consultant
Thomas Lönngren, former Head of EMA and Senior Advisor, NDA Group
Ben Thorpe, Head of Healthcare Investment Banking EMEA, Goldman Sachs
Sten Stovall, Senior Editor, Informa Business Intelligence

Savvas Neophytou, Partner & Head of Life Sciences, Deepbridge Capital
Thierry Laugel, Founder and Managing Partner, Kurma Partners
Guenter Huhle, Head of Johnson & Johnson Innovation, JLABS EMEA
Phil L'Hullier, Head of BD, Europe, European Innovation Hub, MSD
Alain Chevallier, Partner Life Sciences, Truffle Capital
Jonathan Goldstein, Director, Corporate R&D and Venture, Boston Scientific
Bobby Soni, Partner Life Science Investments, IP Group
Zishan Haroon, General Partner, Julz & Co
Amanda Cashin, Co-Founder, Head of Accelerator, Illumina
James Peyer, Managing Partner, Apollo Ventures
Heather Wasserman, Vice President, Eli Lilly
Sree Kant, Head of BD, Life Biosciences
Michael Bloch, Counsel, Allen & Overy
Alexander Belcredi, CEO, PhagoMed
Helen Disney, Founder, Unblocked
Frank Hensel, Principal, High-Tech Gründerfonds
Edward van Wezel, Managing Partner, BioGeneration Ventures
Don DeBethizy, Director, Argenx
Johan Sellström, Co-Founder, CareChain
Peter Finan, Partner, Epidarex Capital
Pablo Prieto, CTO, Lifebit Biotech
Christian Glennie, Director - Equity Research, Healthcare, Stifel
Julie Simmonds, Director Equity Research, Panmure Gordon
Lucie Ellis, Managing Editor, In Vivo
Melanie Senior, Analyst and Specialist Writer, Life Sciences
Mark Allen, CEO, Elevian
Morag Peberdy, Of Counsel, Covington & Burling
Simon Amies, Partner, Covington & Burling
Simon King, Executive Editor, FirstWord Pharma
Nathalie Ter Wengel, European Head Worldwide Business Development, Pfizer
Supa Chantschool, Senior Healthcare Editorial Analyst, GlobalData

Day 1 – Tuesday, February 5th

08.00	REGISTRATION & BREAKFAST
08.50	WELCOME ADDRESS
09.00	<p>KEYNOTE PANEL: AN EVOLVING ECOSYSTEM: GLOBAL INVESTMENT TRENDS AND MODELS</p> <p><i>The healthcare sector continues to see a healthy capital flow. Record-breaking biotech IPOs in the US and Europe are providing exits and returns for investors and the opening of the Hong Kong Stock exchange to listings of none-revenue generating companies is opening up a new public market for fledging life sciences companies. In turn, the boom in VC and PE investments continue apace and larger rounds are bringing innovative companies through the clinic more quickly. Leading investment fund executives debate and discuss the macro healthcare investment trends and the evolution of the global investment ecosystem.</i></p> <p>Clive Cookson, Science Editor, Financial Times (moderator) (CONFIRMED) Tim Haines, Managing Partner Abingworth (CONFIRMED) Johnston Erwin, VP Corporate Business Development, Eli Lilly (CONFIRMED) Sander Slootweg, Managing Partner, Forbion (CONFIRMED) Deborah Harland, Partner, SR One (CONFIRMED) Hubert Birner, Managing Partner, TVM Capital (CONFIRMED) Graziano Seghezzi, Managing Partner, Sofinnova Partners (CONFIRMED)</p>
09.45	<p>KEYNOTE PANEL: PHARMA BD: WHAT'S IN STORE IN 2019?</p> <p><i>Accompanying the boom in investment is the most active period of M&A in over a decade as Pharma are on the hunt for future blockbusters and supplementation of internal R&D and innovation. Global heads of BD & M&A from big pharma outline their views on the M&A boom, what they are looking for in potential acquisitions and their companies' respective foci for the year ahead.</i></p> <p>Ben Thorpe, Head of Healthcare Investment Banking EMEA, Goldman Sachs (moderator) (CONFIRMED) Shaun Grady, VP Global Business Development, AstraZeneca (CONFIRMED) Nigel Sheail, Head of BD&L, Novartis (CONFIRMED) Jochen Gann, Head of Corporate Finance and M&A, Boehringer Ingelheim (CONFIRMED) Boris Zaitra, Head of Group M&A, Roche (CONFIRMED)</p>
10.30	MORNING BREAK

	FINANCE & INVESTMENT	STRATEGY & INNOVATION
11.00	<p>FIRESIDE CHAT: SUPER-SEEDING IN ANTIOBITIC-ALTERNATIVES Alexander Belcredi, CEO and Co-Founder, PhagoMed (CONFIRMED) Lisa Urquhart, Editor, Vantage (moderator) (CONFIRMED)</p>	<p>FIRESIDE CHAT: STRUCTURING A WIN-WIN PLATFORM TECHNOLOGY DEAL Yochi Slonim, CEO, Anima Biotech (CONFIRMED) Adrian Dawkes, Managing Director, PharmaVentures (moderator) (CONFIRMED)</p>
11.20	<p>PANEL: SEEDING AND NURTURING THE NEXT GENERATION <i>Leading seed and early-stage funds outline their views on the current state of seed funding in European life sciences and their strategies for uncovering and financing early-stage innovation and setting them on the path to success.</i></p> <p>Lisa Urquhart, Editor, Vantage (moderator) (CONFIRMED) Juan Garcia, Managing Partner, Bioseed Capital (CONFIRMED) Søren Møller, Managing Partner, Novo Seeds (CONFIRMED) Savvas Neophytou, Partner & Head of Life Sciences, Deepbridge Capital (CONFIRMED) Frank Hensel, Principal, High-Tech Gründerfonds (CONFIRMED) Edward van Wezel, Managing Partner, BioGeneration Ventures (CONFIRMED) Alain Chevallier, Partner Life Sciences, Truffle Capital (CONFIRMED)</p>	<p>PANEL: SYMBIOTIC SUCCESS: THE EVOLVING ROLE OF EARLY STAGE PHARMA COLLABORATION <i>Executives of pharma's innovation sourcing teams discuss the increasing support available to early stage companies from Pharma, what they are on the hunt for in deals, and the keys success factors of collaborations.</i></p> <p>Morag Peberdy, Of Counsel, Covington & Burling (moderator) (CONFIRMED) Phil L'Hullier, Head of BD, Europe, European Innovation Hub, MSD (CONFIRMED) Miriam Frieden, VP Search & Evaluation, Novo Nordisk (CONFIRMED) Tim Luker, Sr. Director, Emerging Technology & Innovation, BD, Eli Lilly (CONFIRMED) Nerida Scott, VP, New Ventures & Transactions, Johnson & Johnson (CONFIRMED)</p>
12.05	<p>PANEL: FUNDING GROWTH: BUILDING BIOTECH LEADERS <i>Executives from the most active and influential venture funds discuss the biotech growth finance environment and how they are supporting and developing companies in the sector with increasingly larger funding rounds and follow-ons.</i></p> <p>Melanie Senior, Analyst and Specialist Writer, Life Sciences (moderator) (CONFIRMED) Dominic Schmidt, Partner, Syncona (CONFIRMED) Chandra P. Leo, Partner, HBM Partners (CONFIRMED) Patrik Sobocki, Investment Manager, Industrifonden (CONFIRMED) Patrick Van Beneden, Partner, Gimv (CONFIRMED) Josh Richardson, Managing Director, Longitude Capital (CONFIRMED)</p>	<p>PANEL: MIND THE GAP: TRANSLATIONAL RESEARCH BOTTLENECKS <i>Despite some improvements to the wider industry's efficiencies, there is still a significant gap between discovery of a new biopharma technology and it becoming an established treatment for patients. Experts discuss the major bottlenecks that still exist and strategies for continuing to bridge the gap from bench to bedside.</i></p> <p>Sam Fazeli, Head of EMEA Research, Bloomberg Intelligence (moderator) (CONFIRMED) Anton Ussi, Operations & Finance Director, EATRIS (CONFIRMED) Sree Kant, Head of BD, Life Biosciences (CONFIRMED) Guenter Huhle, Head of Johnson & Johnson Innovation, JLABS EMEA (CONFIRMED) David Shields, Head, Centers for Therapeutic Innovation East, Pfizer Worldwide Research & Development (CONFIRMED)</p>
12.50	LUNCH BREAK	

	FINANCE & INVESTMENT	STRATEGY & INNOVATION
13.50	<p>FIRESIDE CHAT: SECURING A SERIOUS SERIES A Thomas Holm Pedersen, CEO, NMD Pharma (CONFIRMED)</p>	<p>FIRESIDE CHAT: A BIG DEAL FOR DIABETES Harry Destecroix, Former CEO and Co-founder, Ziyo (invited) David Colpman, Non Exec Director, HRA Pharma, Forendo Pharma (invited)</p>
14.10	<p>PANEL: CVC: THE CORPORATE MULTIPLIER <i>Leading corporate venture executives discuss their ever-increasing influence on the sector, the merits and strategies behind strategic vs. financial investment models, and CVCs as a magnet for other forms of investment.</i></p> <p>Lucie Ellis, Managing Editor, In Vivo (moderator) (CONFIRMED) Sarah Cole, Partner, Takeda Ventures (CONFIRMED) Jasper Bos, SVP and Managing Director, M Ventures (CONFIRMED) Fiona de Hemptinne, Partner, UCB Ventures (CONFIRMED) Heather Wasserman, Vice President, Eli Lilly (CONFIRMED)</p>	<p>PANEL: STRATEGIC PARTNERSHIPS FOR PROGRESSING THROUGH THE CLINIC <i>Biotech executives who have taken their company through key clinical milestones debate the key challenge and success factors in finding the right partners, patient recruitment and risk management to take their assets cost-effectively and punctually through clinical trials.</i></p> <p>Supa Chantschool, Senior Healthcare Editorial Analyst, GlobalData (moderator) (CONFIRMED) Harpreet Singh, CEO, Immatix (CONFIRMED) Jørgen Drejer, CEO, Saniona (CONFIRMED) Nathalie Ter Wengel, European Head Worldwide Business Development, Pfizer (CONFIRMED) Ajan Reginald, CEO, Celixir (CONFIRMED)</p>
14.55	<p>PANEL: WHAT'S NEW WITH YOU? – NEW FUNDS & STRATEGIES <i>Executives of recently closed specialist funds and new funds from existing long-term players explain their investment mandates, what they see as having changed in the venture landscape, and the therapeutic and technology areas getting them excited.</i></p> <p>Madeleine Armstrong, Editor, Vantage (moderator) (CONFIRMED) Thierry Laugel, Founder and Managing Partner, Kurma Partners (CONFIRMED) Laia Crespo, Head of Europe, Sanofi Ventures (CONFIRMED) Peter Finan, Partner, Epidarex Capital (CONFIRMED) Bart Van Hooland, Founding Partner, DROIA (CONFIRMED)</p>	<p>PANEL: BUILDING INTERNATIONAL BIG BIOTECH <i>Executives of companies who are working to build true big biotechs in Europe discuss the challenges and success factors for building and growing large companies, and demonstrating true shareholder value whilst retaining control of their own destiny.</i></p> <p>Don DeBethizy, Director, Argenx (moderator) (CONFIRMED) Sean Marett, CBO & CCO, BioNTech (CONFIRMED) John Dawson, CEO, Oxford BioMedica (CONFIRMED) Franz-Werner Haas, COO, CureVac (CONFIRMED) Andrew Hotchkiss, CEO, Immunocore (CONFIRMED)</p>
15.40	AFTERNOON BREAK	

<p>16.10</p>	<p>PANEL: GENOMIC POTENTIAL: MAPPING THE FUTURE OF MEDICINE Genomics is one of most exciting and fast changing sectors in healthcare, as well as the fastest growing with next generation sequencing market is expected to quadruple in size in just 5 years from 2015, reaching €19Bn by 2020. Executives and key stakeholders debate and discuss impact genomics is having on healthcare today, investing now to realise future potential, as well as the bottlenecks and how the industry can work together to overcome them.</p> <p>Amanda Cashin, Co-Founder and Head of Accelerator, Illumina (CONFIRMED) Pablo Prieto, CTO, Lifebit Biotech (CONFIRMED) Anthony Joseph, CTO, Unite Genomics (CONFIRMED) Carina Namih, Partner, Episode 1 (CONFIRMED) Alex Mok, CEO, Mantra (invited) Leila Zegna, Founding Partner, Kindred Capital (invited)</p>
<p>16.50</p>	<p>FIRESIDE CHAT: TRANSFORMING AND ACCELERATING LIFE SCIENCE INNOVATION Jackie Hunter, Chief Executive, BenevolentBio (CONFIRMED) Adrian Dawkes, Managing Director, PharmaVentures (moderator) (CONFIRMED)</p>
<p>17.10</p>	<p>PANEL : PLAYING THE LONG GAME - IN CONVERSATION WITH LONGEVITY LEADERS Terry O'Dwyer, Co-CEO, Longevity Leaders (moderator) (CONFIRMED) James Peyer, Managing Partner, Apollo Ventures (CONFIRMED) Tristan Edwards, CEO, Life Biosciences (CONFIRMED) Matthew Scholz, CEO, Oisin Biotechnologies (CONFIRMED) Mark Allen, CEO, Elevian (CONFIRMED)</p>
<p>17.50</p>	<p>NETWORKING DRINKS</p>

Day 2 – Wednesday, February 6th

08.00	REGISTRATION & BREAKFAST
09.20	WELCOME REMARKS
09.30	<p>KEYNOTE PANEL: LOOKING EAST TO NEW CAPITAL SOURCES</p> <p><i>VCs and strategic investors from Asia are making an increasingly significant impact on funding of US and European life science companies. In China, government reforms designed to expedite innovation in life sciences are driving a wave of private capital from Chinese VCs and corporate strategics being ploughed into US and European life science companies who are on prowl for assets. Leading Asian investors and executives who have successfully raised capital with investment partners discuss how long this hunger will continue, their views on finding assets in partners in the US compared to Europe, and how biotechs can best position themselves to benefit and secure investment partners.</i></p> <p>John Hodgson, Independent Consultant (moderator) (CONFIRMED) Stephan Lensky, CBO, EpiMab (CONFIRMED) Katherine Cohen, Venture Partner, Panacea Venture (CONFIRMED) Aditya Puri, Partner – Investments, Xeraya Capital (CONFIRMED) Bin Li, Partner and Managing Director, Ally Bridge Group (invited) Theodora Harold, CFO, Crescendo Biologics (invited) Bosun Hau, Partner and Head of Global Healthcare, Sailing Capital (invited) Marietta Wu, Managing Partner, Quan Capital (invited) John Ridden, CEO, Blueberry Therapeutics (invited)</p>
10.10	<p>KEYNOTE FIRESIDE CHAT: LOOKING WEST TO BUOYANT PUBLIC MARKETS</p> <p><i>The US IPO market in the US has seen record life science listings and record volumes of capital pouring in to them in the last 18 months and, alongside the homegrown US biotechs has come a number of listings and dual-listings of some of European biotech leaders. Executives from these firms talk through the decision, keys success factors and future plans as they build their companies on both sides of the Atlantic.</i></p> <p>Adam Kostyal, Senior Vice President, Nasdaq (moderator) (CONFIRMED) Piers Morgan, CFO, Verona Pharma (CONFIRMED)</p>
10.30	MORNING BREAK

	FINANCE & INVESTMENT	STRATEGY & INNOVATION
11.00	<p>FIRESIDE CHAT: TAKING DIGITAL PUBLIC Lord Drayson, CEO, Sensyne Health (CONFIRMED) Michael Bloch, Counsel, Allen & Overy (moderator) (CONFIRMED)</p>	<p>FIRESIDE CHAT: THE PAYER'S PERSPECTIVE Carole Longson, former Director of NICE and CSO, ABPI (CONFIRMED) Thomas Lönngren, former Head EMA & Sr Advisor, NDA Group (moderator) (CONFIRMED)</p>
11.20	<p>PANEL: BRIDGING THE GAP: THE RISE OF THE CROSSOVER INVESTMENT MODEL <i>With a number of new specific crossover funds launching in Europe to match a similar trend in the US, executives of investment funds for crossover investment, and executives who have been backed by them, discuss the importance of this funding as a bridge to realising value and a successful start on the public markets.</i></p> <p>Simon Amies, Partner, Covington & Burling (moderator) (CONFIRMED) Tom Burt, Partner, Crossover Fund, Sofinnova (CONFIRMED) Francesco De Rubertis, Co-Founder and Partner, Medicxi (CONFIRMED) Alex Pasteur, Partner, F-Prime Capital Partners (CONFIRMED)</p>	<p>PANEL: THE JOURNEY TO A VALUE-BASED APPROACH IN HEALTHCARE <i>Executives, regulators, payers and experts debate how far the industry has come, and still needs to go as a whole, in managing the cultural shift towards a sustainable patient-centric culture, strategies to ensure alignment in patient value and shareholder value, and the role of all healthcare stakeholders in this shift.</i></p> <p>Thomas Lönngren, former Head EMA & Sr Advisor, NDA Group (CONFIRMED) Carole Longson, former Director of NICE and CSO, ABPI (CONFIRMED) John Bowis, Former MP, MEP and UK Health Minister (CONFIRMED) Trevor Leighton, VP Market Market Access, argenx (CONFIRMED)</p>
12.05	<p>PANEL: BEYOND VENTURE: PUBLIC SPECIALISTS <i>As the European biotech markets continues to mature, companies who have listed still continue to need financial support from those who better understand the biotech business model. Executives from specialist life sciences investors with public equity investments, and healthcare and biotech fund managers discuss the role they are playing in helping to commercialise maturing public corporates.</i></p> <p>Sten Stovall, Senior Editor, Informa Business Intelligence (CONFIRMED) Geraldine O'Keeffe, Partner Public Equities, LSP (CONFIRMED) David Pinniger, Fund Manager - Biotechnology, Polar Capital (CONFIRMED) Mattias Häggblom, Portfolio Manager - Global Healthcare, Swedbank Robur (CONFIRMED) Ivo Staijen, Portfolio Manager, HBM Partners (CONFIRMED)</p>	<p>PANEL: DE-RISKING IN THE QUEST FOR COMMERCIALISATION <i>As biopharma companies follow the yellow brick road to commercialising their products, finding the balance right balance in capital runway, ongoing R&D and looking to the future of preparing for reaching the 'Emerald City' is key. Executives discuss the common pitfalls and key strategies to think about and implement early through late stage clinical trial progress, manufacturing supply chain development and regulatory approval.</i></p> <p>Simon King, Executive Editor, FirstWord Pharma (moderator) Dimitri Dimitriou, CEO, ImmuPharma (CONFIRMED) Nikolaj Sorensen, CEO, Orexo (CONFIRMED) David Colpman, Non Exec Director, HRA Pharma, Forendo Pharma (CONFIRMED)</p>
12.50	LUNCH BREAK	

13.50	<p>PANEL: BLOCKCHAIN IN HEALTHCARE: QUICK OUT OF THE BLOCKS <i>The healthcare industry has been increasingly turning to digital technology, and that digital technology creating a tsunami of data - how this is stored and accessed across the ecosystem can be transformed by the adoption of blockchain. Experts explain the numerous applications of blockchain including smart contracts with suppliers, streamlined clinical trial management and empowerment of patients with their own data.</i></p> <p>Helen Disney, Founder, Unblocked (moderator) (CONFIRMED) Mark Hahnel, Associate Founder, Genomes.io (CONFIRMED) Alexis Normand, Head of Embleema Blockchain Consortium, Embleema (CONFIRMED) Johan Sellström, Co-Founder, CareChain (CONFIRMED) Natalie Pankova, COO, Project Shivom (CONFIRMED)</p>
14.30	<p>PANEL: WHAT'S HOT, WHAT'S NOT (LIVED UP TO THE HYPE)? <i>The biopharma space is littered with examples of 'the next big thing' that is going to revolutionise medicine, and investment dollars flow soon afterwards. Has this flood of investment always matched the outcome? Investors look backward to where the hype has not been realised and lessons can be learned, and to the future of what, in their opinion, we really should be excited about.</i></p> <p>Andy Smith, Director-Analyst, Healthcare, Edison (moderator) (CONFIRMED) Zishan Haroon, General Partner, Julz & Co (CONFIRMED) Dmitry Kuzmin, Managing Partner, 4BIO Capital Partners (CONFIRMED) Bobby Soni, Partner Life Science Investments, IP Group (CONFIRMED) Jason Foster, Managing Partner, Health Equity Consulting (CONFIRMED)</p>
15.10	<p>PANEL: INDUSTRY FORESIGHT: WHERE ARE WE HEADING? <i>Leading analysts highlight and debate what they see as the biggest industry trends that will affect the biopharma industry in the years to come. What are the biggest hurdles that need to be overcome, and what opportunities that may arise as the industry develops?</i></p> <p>Andy Smith, Director-Analyst, Healthcare, Edison (moderator) (CONFIRMED) Gary Waanders, Managing Director - UK Healthcare Research, Bryan, Garnier & Co. (CONFIRMED) Mick Cooper, Healthcare & Life Sciences Analyst, Trinity Delta (CONFIRMED) Christian Glennie, Director - Equity Research, Healthcare, Stifel (CONFIRMED) Julie Simmonds, Director Equity Research, Panmure Gordon (CONFIRMED)</p>
15.50	CLOSE OF CONGRESS